Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

NCT02377999 Phase 2 COMPLETED

An exploratory open label, single treatment trial of anogenital warts with Picato® repeated up to 2 times with two weeks intervals.

Details

Lead sponsor	LEO Pharma
Phase	Phase 2
Status	COMPLETED
Enrolment	40
Start date	2015-02
Completion	2015-11

Conditions

• Anogenital Warts

Interventions

• Picato

Primary outcomes

• Number of incidence and severity of Local Skin Reactions (LSR) — Measured two weeks after every treatment and final measurement 2 weeks after last treatment

Countries

Denmark